Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Dowell

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Translational Oncology|June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitorsVatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Clinical Lung Cancer|July 14, 2023
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never SmokedJ Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, et al.
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Molecular Cancer Therapeutics|August 11, 2021
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling PathwayWei Zhang, Ankur S Bhagwath, Zeeshan Ramzan, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing DataBing Song, Kaiwen Wang, Saiyang Na, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
JTO Clinical and Research Reports|January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry AnalysisMargaret Stalker, Connor B Grady, Alex Watts, et al.
Nature Cancer|June 27, 2025
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomesBing Song, Kaiwen Wang, Saiyang Na, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Translational Oncology|June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitorsVatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
Clinical Lung Cancer|July 14, 2023
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never SmokedJ Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, et al.
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Molecular Cancer Therapeutics|August 11, 2021
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling PathwayWei Zhang, Ankur S Bhagwath, Zeeshan Ramzan, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing DataBing Song, Kaiwen Wang, Saiyang Na, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
JTO Clinical and Research Reports|January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry AnalysisMargaret Stalker, Connor B Grady, Alex Watts, et al.
Nature Cancer|June 27, 2025
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomesBing Song, Kaiwen Wang, Saiyang Na, et al.
Pageof 6